LIMN

Healthcare Biotechnology

Liminatus Pharma, Inc.

$3.88

+0.00 +0.00% today

Price History

Not enough data

Key Stats

Market Cap

5.21M

Avg Volume

448,885

EPS

-$23.50

52W High

$141.50

52W Low

$3.29

Div. Yield

0.0%

Valuation

P/B Ratio

14.42

EV/EBITDA

-0.84

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Assets

(95.7%)

Liquidity & Leverage

Current Ratio

1.12

Quick Ratio

0.99

Debt / Equity

4.80

Total Cash

3.02M

Total Debt

1.44M

About

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.

liminatuspharma.com